Table 1 Demographic and clinical characteristics of patients with SLCO1B1 С521Т polymorphism (Group A) and MDR1 С3435Т polymorphism (Group B) who underwent statin treatment (Rosuvastatin, Atorvastatin and Simvastatin)
Characteristic | Rosuvastatin | Atorvastatin | Simvastatin | |||
|---|---|---|---|---|---|---|
Subgroup A I (n = 30) | Subgroup B I (n = 30) | Subgroup A II (n = 30) | Subgroup B II (n = 30) | Subgroup A III (n = 30) | Subgroup B III (n = 30) | |
Sex, male/female | 6 (20%)/ 24 (80%) | 8 (26,6%)/ 22 (73,4%) | 7 (23%)/ 23 (77%) | 9 (30%)/ 21 (70%) | 5 (16,7%)/ 25 (83,3%) | 8 (26,6%)/ 22 (73,4%) |
Average age, years (М ± m) | 55.2 ± 1.47 | 54.7 ± 1.42 | 57.3 ± 1.59 | 58.2 ± 1.61 | 55.9 ± 1.63 | 56.8 ± 1.54 |
Hyperlipoproteinemia Type IIa | 16 (53%) | 18 (60%) | 17 (56,7%) | 19 (63,3%) | 18 (60%) | 20 (66,7%) |
Hyperlipoproteinemia Type IIb | 14 (46,7%) | 12 (40%) | 13 (43,3%) | 11 (36,7%) | 12 (40%) | 10 (33,3%) |
Arterial hypertension Degree I–II | 25 (83,3%) | 24 (80%) | 29 (96,7%) | 27 (90%) | 30 (100%) | 28 (93,3%) |